Tag Archives: Aptamers Market

Increasing Research and Development Activities to Put Global Aptamers Market on Growth Track

Aptamers Market: Snapshot

Aptamers offer immense potential for the development of unique applications in the field of fundamental research, drug selection, clinical diagnosis, and therapies. They have gained worldwide preference over antibodies owing to the former’s key benefits – greater binding affinity, high specificity, and the ability to not destroy neighboring cells. The major factors driving the aptamers market is growing interest of research scientists in the field of aptamer technology and increasing support from private organizations. On the flip side, lack of knowledge about this technology results in low acceptance. Moreover, ethical issues and inadequate regulatory policies related to aptamer technology threaten to impede the growth of this market.

The worldwide market for aptamers is slated to exhibit an impressive CAGR of 73.1% during the course of the forecast period, rising to a value of US$4.3 bn by 2019.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

Growing Application of Aptamers in Therapeutics

Accounting for the leading share by type, nucleic acid aptamers are anticipated to present an opportunity worth US$3.3 bn by 2019, developing at an astounding CAGR of 73.4% during the forecast period. Nucleic acid aptamers have been gaining much traction as a substitute for protein-based targeting approaches. This segment is also projected to be driven by a rising number of leading players collaborating with various organizations and research institutes in order to develop customized nucleic acid aptamers. The introduction of novel selection processes and advanced technology-based aptamers.

On the basis of application, therapeutics is slated to enjoy the dominant share in the aptamers market, registering a strong CAGR of 80.3% during the forecast period to amount to an estimated US$1.4 bn by 2019. The use of aptamers has revolutionized the field of therapeutic development and a number of companies are working toward developing different aptamers for the treatment of a variety of diseases. This is a key factor boosting the uptake of aptamers in therapeutics. Other applications of aptamers include diagnostics and research.

Consistent Collaborations and Investments in R&D to Lend Asia Pacific a Helping Hand

The global market for aptamers is segmented on the basis of geography into Europe, North America, Asia Pacific, and Rest of the World. At the start of the forecast period, North America accounted for more than two-fifth of the overall aptamers market, driven by the strong presence of established companies and growing investments made by them in the field. Europe followed suit, powered by the rising usage of aptamer technologies by small-scale industries. Growth of the aptamers market in this region can also be attributed to consistent efforts and collaborations by players in order to enter the market.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

Asia Pacific is projected to witness strong growth by 2019 thanks to impressive investments in R&D, backed by encouraging policies by various governments for the expansion of the pharmaceutical sector. The growing incidence of chronic disorders, such as Alzheimer’s and HIV/AIDS, in APAC has upped the demand for novel therapeutics, which in turn drives the demand for aptamers. Brimming with opportunities in pharmaceutical and diagnostics, the aptamers market in Asia Pacific is sure to attract a lot of attention in the years to come as key players continue to expand and increase product distribution in China, India, and other lucrative countries.

Some of the prominent companies competing in the global aptamers market are Base Pair Biotechnologies, Inc., Vivonics, Inc., SomaLogic Inc., Aptagen, LLC, Aptus Biotech S.L., NeoVentures Biotechnology, Aptamer Solutions Ltd, TriLink BioTechnologies, Inc., AM Biotechnologies, LLC, and Aptamer Sciences, Inc. There is a high degree of rivalry among the key players and this has brought about a surge in investments for the development of novel aptamers.


Global Aptamer Market: Advancements in Aptamer Technology to Expand Market at 73.1% CAGR

Aptamers are chemically synthesized single stranded oligonucleotides that are used to inhibit variety of target proteins and antigens. Aptamers specifically bind to a range of micromolar to macromolar molecular targets. They are basically of two types namely nucleic acid aptamers and peptide aptamers. Nucleic acid aptamers have the strand of oligonucleotides while peptide aptamers contain short peptide domain in its structure. Normally aptamers can be generated by the aptamer selection process known as SELEX process. Aptamer technology applies in number of areas such as diagnostics, food safety, research applications and therapeutics in number of industrial sectors like pharmaceutical, research laboratories and biotechnology.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

Transparency Market Research, a leading U.S based market research firm analyses the global market for aptamers and estimates the CAGR of 73.1% for the period 2013 – 2019. This is majorly due to increasing research and development activities by scientists coupled with increasing participation of government and private organizations in the U.S. and U.K. towards the development of this field. For example, in June 2014, Somalogic, Inc. received funding from Bill and Melinda Gates Foundation to develop SOMAmer based tuberculosis biomarker assay for the identification of patient’s tuberculosis.

The other factors such as advancement in aptamer selection technologies coupled with various advantages of aptamers over monoclonal antibodies will further drive the market growth. Several modifications of the SELEX procedure have been introduced to improve aptamer selectivity or to reduce selection time. Subtractive SELEX, automated SELEX and atomic force microscopy-SELEX are some of the modified SELEX processes available for aptamer selection with desired features. Companies like Archemix, Somalogic, Inc. and Aptamer Sciences, Inc. are constantly involved in collaboration strategy with number of biotechnology companies to develop their aptamer business. For example, Archemix collaborated with Elan to discover aptamers for treatment of autoimmune diseases. Thus, these types of collaboration will help companies to develop new aptamers hence drives the market growth. Moreover, large number companies have increased their research expenses on aptamers after first aptamer- Macugen approved by USFDA in 2004. For example, Germany-based NOXXAN Pharma AG has three aptamers namely NOX-E63, NOX A-12 and NOX-H94 under clinical pipeline. NOX-E63 and NOX A-12 are under phase II clinical studies. The approval of these aptamers in future would definitely boost the market growth of aptamers. Other features of aptamers like favorable toxicological property, high stability, ease of synthesis and rapid tissue penetration would significantly contribute to the growth of the market.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

The factors mentioned above are driving the development and commercialization of aptamers worldwide. However, unfavorable regulatory environment, lack of universal rule coupled with lack of knowledge of aptamers among research scientists will restrain the market growth. For example, there is no formal regulatory guideline that can satisfactorily address the quality and safety of aptamer molecule. Additionally, countries like Europe demands tedious documentation to start clinical trials on aptamers which will further restrain the market growth of aptamers.

New Trends of Aptamers Market with Worldwide Industry Analysis to 2019

The growing use of aptamers in drug discovery, pharmaceutical studies, as well as disease treatment will help drive the global aptamers market through the current decade, says Transparency Market Research in a recent study. The report is titled ‘Aptamers Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.’ According to the report, the global aptamers market was valued at US$93.0 million in 2012, and it is expected that the market will reach a valuation of US$4,333.0 million by 2019. This translates to a remarkable CAGR of 73.1% between 2013 and 2019.

However, the report also warns that the growth in the global aptamers market will be restrained to some extent ethical issues associated with aptamers derived from animals. This drawback will be further compounded by strict regulatory mandates designed around aptamers. However, these drawbacks can be overcome by companies in the global aptamers market by modifying aptamers chemistry. For instance, animal-derived aptamers can be replaced by aptamers obtained via the in-vitro process.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

For the purpose of this study, the global aptamers market is segmented on the basis of types, applications, and geography. The types of aptamers studied in the report include peptide and nucleic acid aptamers. The segment of nucleic acid aptamers was not only the largest as of 2012, but is also expected to be the fastest growing over the report’s forecast period. This is chiefly owing to the widespread use of nucleic acid aptamers in the R&D sector.

Likewise, the applications analyzed in the report are: Diagnostics, therapeutics development, research and development, and others. Of these, the diagnostics segment will report consistent growth over the next four years as the demand for aptamers for biomedical diagnostics, biomarker development, and molecular imaging remains steady. However, in terms of pace of growth, therapeutics development applications will outpace all other application segments over the report’s forecast period.

From the geographical standpoint, the aptamers market for the following regions is studied: North America, Asia Pacific, Europe, and Rest of the World. Thanks to several key players in the aptamers market being based in the United States, the North America region was identified as the largest market for aptamers in 2012. This factor also creates an environment that fosters R&D related to aptamers.

The Europe aptamers market was the second largest from the global standpoint. According to the findings of the report, Europe constituted about 35% of the global aptamers market in 2012. Small scale industries play a key role in keeping the Europe aptamers market firmly on the growth track. The Asia Pacific market is currently brimming with opportunities in diagnostics and pharmaceuticals, enabling the region to post the highest CAGR between 2013 and 2019.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

TMR’s report also conducts a detailed analysis of the competitive scenario in the global aptamers market, which is characterized by intense competition. A high degree of competition has stimulated higher investments the development of novel aptamers. Leading market participants include: Somalogic, Inc., Aptamer Science, Inc. NOXXAN Pharma AG, and Aptagen, Inc.


Global Aptamers Market: Modification of Chemical Structure to Prove to be Beneficial, says TMR

The global aptamers market is oligopolistic in nature, led by key players such as Somalogic, Inc., Aptamer Sciences, Inc. and Aptagen, Inc. The top three companies account for 57.8% of the market in 2012. These companies are investing continually in research and development in order to develop novel aptamers for use in various applications such as therapeutics and diagnostics. Companies are striving to gain a better understanding of human biology and diseases, discovery of new drugs, and the development of new diagnostic tests. Companies such as Aptamer Sciences, Inc. provide high quality and cost effective custom aptamers to target various molecules based on specific customer requirements. The company offers more than 200 validated DNA aptamer sequencing for a variety of human target proteins. A new report by Transparency Market Research (TMR) states that antibodies are expected to be a major threat for the aptamers market. As the market for antibodies is well-established, researchers are reluctant to switch to the underdeveloped aptamers market. Thus, the threat of substitute is expected to be high to medium.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

According to the report, the global aptamers market is expected to reach US$4,333.0 mn by 2019. On the basis of type, the nucleic acid aptamers market is expected to lead and be worth US$4,333.0 mn by 2019. By application, the market is expected to be led by the therapeutics development segment, which is likely to be worth US$1,452.4 by 2019. This segment is also likely to be expand at the maximum CAGR from 2013 to 2019. On the basis of geography, the market is expected to continue to be led by North America. The North America aptamers market is estimated to reach US$2,029.1 mn by 2019 owing to increasing scientific research and development activities by key players for the development of aptamers.

Rising Support from Various Organizations to Drive Aptamers Market

Aptamers have a great potential and thus, many private organizations in the U.S. and the U.K. are engaged in funding and further development of the aptamer field. This is expected to drive the growth of the market. Aptamers are increasingly being perceived as an attractive solution for research applications owing to the unique production methodology. The production of aptamers do not require animals, thus avoiding animal abuse and death. This eliminates the need for companies to send animal protocol the Institutional Animal Care and Use Committee (IACUC) for aptamer development. Another factor driving the market is the high specificity and selectivity of aptamers, owing to which, the volume required for analysis can be reduced. This helps in increasing the speed of the research analysis, driving their demand.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

Lack of Formal Regulatory Guidelines to Pose a Challenge

“There are no formal regulatory guidelines aptamers, which specifically addresses the quality expectations of these drugs.,” says a TMR analyst. The regulatory expectation of aptamer-based drugs is still evolving and the development of regulatory guidelines, which would satisfactorily address quality and safety requirements is challenging. However, aptamer modifications can be made to increase half-life or to enhance therapeutic abilities. In addition to this, chemical structure modification of aptamer can also prove to be beneficial.

This information is based on the findings of a report published by Transparency Market Research titled “Aptamers Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”


At 73.1% CAGR to 2019, Global Aptamers Market Reaps Benefits of Higher use of Aptamers in Therapeutics Development

Aptamers have been drawing the attention of several scientists in the last few years, not only because of their antibody replacement, but also because they have unique features, including low cost, thermal stability, and wide applications. Aptamers are oligonucleotides that bind to a particular target molecule. Aptamers exhibit high affinity and specificity to diverse target molecules, such as bacteria, proteins, or the whole cell. The growing interest of research scientists in aptamers is expected to encourage the growth of the overall market in the next few years. Moreover, the intensive research and development activities carried out by the key players for expansion of product portfolio and application will accelerate the growth of the market in the near future.

According to a research study released by Transparency Market Research (TMR), the global market for aptamers is estimated to reach a value of US$4.33 bn by the end of 2019, rising from US$93 mn in 2012. The market is predicted to register an exponential 73.10% CAGR between 2013 and 2019. In this blog, TMR provides answers to several questions concerning the remarkable growth of the global aptamers market, along with key dynamics that are projected to stimulate the growth of the market in the near future.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

Oligonucleotide Aptamers being Explored as New Tools for Targeted Cancer Therapy

Since the discovery of aptamers in the early 1990s, significant efforts have been made to make them clinically relevant for diseases such as HIV, cancer, and macular degeneration. The first aptamer-based therapeutic approved by the U.S. Food and Drug Administration in 2004 was for the treatment of age-related macular degeneration. Several other aptamers are presently being evaluated in clinical trials. In terms of applications, the global aptamer market is projected to be driven by the demand from diagnostics and therapeutics development segments.

SELEX technology is used to develop aptamers for cell surface biomarkers. The oligonucleotide aptamers developed with the help of Cell-SELEX technology have boosted personalized cancer research. Traditional cancer treatments such as radiotherapy, chemotherapy, photothermal therapy, and photodynamic therapy can cause adverse side effects in patients owing to their associated nonspecific toxicity. Antibody-mediated targeted cancer therapy is a better alternative as it is highly specific and has fewer side effects. However, the high cost of production and potential immunogenicity limits the clinical applications of antibody-mediated therapy. To overcome these hindrances, oligonucleotide aptamer-based targeted therapeutics have been explored. Research studies have revealed a number of advantages of the aptamer technology over antibody therapies for the treatment of cancer.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

Aptamer-Targeted Nanoparticle Delivery: A Novel Way for Drug Delivery

Nanoparticles, ranging in size from 5-200 nm, are being developed for various medical applications. Nanoparticles have interesting features such as a large surface for enhanced aptamer and drug loading, uniform size and shape for excellent biodistribution, and biocompatibility for clinical applications. Nanoparticles are effective vehicles to increase the half-life as well as the drug-payload capacity of aptamer-mediated drug delivery. Conjugation of aptamers with nanoparticles such as copolymers and liposomes offer an excellent opportunity for drug delivery owing to their enhanced biodegradability and biocompatibility. Nanoparticles also offer exceptional magnetic and photothermal performance.

It would thus be interesting to see how aptamer-targeted nanoparticle delivery would change the future outlook of cancer therapeutics.